Bristol Myers Squibb’s Augtyro Granted FDA Priority Review for NTRK-Positive Locally Advanced, Metastatic Solid Tumors

Augtyro is a potential best-in-class tyrosine kinase inhibitor that targets ROS1- or NTRK-positive locally advanced or metastatic solid tumors.

Source link
#Bristol #Myers #Squibbs #Augtyro #Granted #FDA #Priority #Review #NTRKPositive #Locally #Advanced #Metastatic #Solid #Tumors